CMET-29. HORMONE RECEPTORS STATUS: A STRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER
Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Caroline Bailleux(Centre Antoine Lacassagne), William Jacot(Inserm), Eva Johanna Kantelhardt(Martin Luther University Halle-Wittenberg), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Simon Thézenas(Institut de Recherche en Cancérologie de Montpellier), Jean Marc Ferrero(Centre Antoine Lacassagne), Christoph Thomssen(Martin Luther University Halle-Wittenberg), A. Braccini(Centre Azuréen de Cancérologie), Federica Miglietta(University of Padua)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k